These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34378436)

  • 21. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
    Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H
    Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
    Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
    Toledo JB; Bjerke M; Da X; Landau SM; Foster NL; Jagust W; Jack C; Weiner M; Davatzikos C; Shaw LM; Trojanowski JQ;
    JAMA Neurol; 2015 May; 72(5):571-81. PubMed ID: 25822737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased soluble amyloid-beta causes early aberrant brain network hypersynchronisation in a mature-onset mouse model of amyloidosis.
    Ben-Nejma IRH; Keliris AJ; Daans J; Ponsaerts P; Verhoye M; Van der Linden A; Keliris GA
    Acta Neuropathol Commun; 2019 Nov; 7(1):180. PubMed ID: 31727182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
    Shokouhi S; Campbell D; Brill AB; Gwirtsman HE;
    Brain Pathol; 2016 Sep; 26(5):664-71. PubMed ID: 27327527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High performance plasma amyloid-β biomarkers for Alzheimer's disease.
    Nakamura A; Kaneko N; Villemagne VL; Kato T; Doecke J; Doré V; Fowler C; Li QX; Martins R; Rowe C; Tomita T; Matsuzaki K; Ishii K; Ishii K; Arahata Y; Iwamoto S; Ito K; Tanaka K; Masters CL; Yanagisawa K
    Nature; 2018 Feb; 554(7691):249-254. PubMed ID: 29420472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials.
    Xiong C; Luo J; Agboola F; Li Y; Albert M; Johnson SC; Koscik RL; Masters CL; Soldan A; Villemagne VL; Li QX; McDade EM; Fagan AM; Massoumzadeh P; Benzinger T; Hassenstab J; Bateman RJ; Morris JC;
    Alzheimers Dement; 2019 Nov; 15(11):1448-1457. PubMed ID: 31506247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
    Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
    J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early pathologic amyloid induces hypersynchrony of BOLD resting-state networks in transgenic mice and provides an early therapeutic window before amyloid plaque deposition.
    Shah D; Praet J; Latif Hernandez A; Höfling C; Anckaerts C; Bard F; Morawski M; Detrez JR; Prinsen E; Villa A; De Vos WH; Maggi A; D'Hooge R; Balschun D; Rossner S; Verhoye M; Van der Linden A
    Alzheimers Dement; 2016 Sep; 12(9):964-976. PubMed ID: 27107518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on biomarkers for amyloid pathology in Alzheimer's disease.
    Ashton NJ; Schöll M; Heurling K; Gkanatsiou E; Portelius E; Höglund K; Brinkmalm G; Hye A; Blennow K; Zetterberg H
    Biomark Med; 2018 Jul; 12(7):799-812. PubMed ID: 29902934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NP03, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats.
    Wilson EN; Do Carmo S; Welikovitch LA; Hall H; Aguilar LF; Foret MK; Iulita MF; Jia DT; Marks AR; Allard S; Emmerson JT; Ducatenzeiler A; Cuello AC
    J Alzheimers Dis; 2020; 73(2):723-739. PubMed ID: 31868669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.
    Vos SJB; Gordon BA; Su Y; Visser PJ; Holtzman DM; Morris JC; Fagan AM; Benzinger TLS
    Neurobiol Aging; 2016 Aug; 44():1-8. PubMed ID: 27318129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.